Allogeneic CAR T Recognized for Cutaneous T-Cell Lymphomas
CTX-130 is being investigated in phase 1 studies for relapsed/refractory T or B-cell malignancies and renal cell carcinoma.
The FDA has granted
“The RMAT designation is an important milestone for the CTX130 program that recognizes the transformative potential of our cell therapy in patients with T-cell lymphomas based upon encouraging clinical data to date,” Phuong Khanh Morrow, MD, FACP, chief medical officer, CRISPR Therapeutics, said in a statement.1 "We continue to work with a sense of urgency to bring our broad portfolio of allogeneic cell therapies to patients in need.”
CTX130 is a CD70-targeting gene-edited investigational CAR T therapy being evaluated in 2 ongoing phase 1, multi-center, open-label clinical trials. The COBALT-LYM trial (NCT04502446) is assessing the therapy in relapsed/refractory T or B-cell malignancies and the COBALT-RCC trialis assessing it in relapsed/refractory renal cell carcinoma. Both trials are assessing the safety and efficacy of escalating dose levels, with primary outcomes of adverse event incidence/dose limiting toxicities and overall response rate. Both trials’ secondary outcomes are progression free survival and overall survival. CTX130 has also received orphan drug and regenerative medicine advanced therapy designations from the FDA.
READ MORE:
CRISPR Therapeutics, along with its collaborator Vertex Pharmaceuticals, also just announced that they will be submitting biologics license applications (BLA) for
“We are pleased to have concluded our exa-cel pre-submission meetings with regulators and are excited that FDA has granted a rolling review,” Nia Tatsis, PhD, Executive Vice President and Chief Regulatory and Quality Officer, Vertex, said in a statement.2 “We continue to work with urgency to bring forward the first CRISPR therapy for a genetic disease, and one that holds potential to transform the lives of patients with sickle cell disease or beta thalassemia.”
Exa-cel is being investigated in the ongoing phase 1/2/3 open-label CLIMB-111 and CLIMB-121 trials for SCD and TDT, the long-term CLIMB-131 study, and the ongoing, phase 3, open-label CLIMB-141 and CLIMB-151 trials which are currently enrolling participants.
The submission news follows in the footsteps of the FDA’s landmark approval of bluebird bio’s
REFERENCES
1. CRISPR Therapeutics announces FDA regenerative medicine advanced therapy (RMAT) designation granted to CTX130™ for the treatment of cutaneous t-cell lymphomas (CTCL). News release. CRISPR Therapeutics https://finance.yahoo.com/news/crispr-therapeutics-announces-fda-regenerative-120000758.html. September 28, 2022.
2. Vertex and CRISPR Therapeutics Announce Global exa-cel Regulatory Submissions for Sickle Cell Disease and Beta Thalassemia in 2022. News release. Vertex Pharmaceuticals. September 27, 2022. https://investors.vrtx.com/news-releases/news-release-details/vertex-and-crispr-therapeutics-announce-global-exa-cel
3. FDA approves first cell-based gene therapy to treat adult and pediatric patients with beta-thalassemia who require regular blood transfusions. News release. FDA. August 17, 2022. https://www.fda.gov/news-events/press-announcements/fda-approves-first-cell-based-gene-therapy-treat-adult-and-pediatric-patients-beta-thalassemia-who?utm_medium=email&utm_source=govdelivery
Newsletter
Stay at the forefront of cutting-edge science with CGT—your direct line to expert insights, breakthrough data, and real-time coverage of the latest advancements in cell and gene therapy.
Related Articles
- Around the Helix: Cell and Gene Therapy Company Updates – September 17, 2025
September 17th 2025
- ImmunoLogic, Episode 6: "The Future of Personalized Cancer Vaccines”
September 15th 2025
- Top News in Lymphoma Cell Therapy for World Lymphoma Awareness Day 2025
September 15th 2025
- Duchenne Action Month 2025: Looking Back at News and Expert Insights
September 14th 2025